RKH Klinken Ludwigsburg-Bietigheim gGmbH — Clinical Trial Site

31 Registered trials

15 Currently recruiting

Organisation

RKH Klinken Ludwigsburg-Bietigheim gGmbH

Location

Ludwigsburg, Germany

Identifier

ORG-100043319

Address

Posilipostraße 4, Mitte, 71640, Germany

Departments

Abteilung Haematoonkologie
Clinic for Gynaecology and Obstetrics
Frauenklinik
Gynaecology
Gynaecology and Obstetrics
Gynäkologie
Gynecological Oncology
Innere Medizin, Gastroenterologie, Hämato-Onkologie, Pneumologie, Diabetologie und Infektiologie
Klinik f Inn Med, Gastroenterologie, Haemato-Onkologie, Pneumologie, Diabetologie und Infekt
Klinik f. Innere Med. Gastroenterologie, Hämato-Onkologie, Pneumologie, Diabetologie u. Infektiolog.
Klinik f. Innere Medizin, Gastroenterologie, Haemato-Onkologie, Pneumologie, Diabetologie u Infekt
Klinik für Frauenheilkunde und Geburtshilfe
Klinik für Geburtshilfe und Frauenheilkunde
Klinik für Innere Medizin
Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie und Infektiologie
Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie, Infektiologie
Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Pneumologie, Diabetologie
Klinik für Neurochirurgie
Klinik für Radioonkologie und Strahlentherapie
Krebszentrum Nord-Württemberg
Krebszentrum Nordwürttemberg
Med. Klinik I
Neuroradiologie

Clinical trials at this site (31)

Search interface

Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending

2025-522377-12-00 metastatic colorectal cancer 5
Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants … Pending

2025-522692-29-00 Subacute Moderate to Severe Traumatic Brain Injury (TBI 4
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial Recruiting

2024-516544-26-00 acute ischemic stroke 4 2026-03-30
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap… Recruiting

2022-502889-24-00 chemotherapy-induced polyneuropathy (CIPN) 5 2024-02-13
Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy Recruiting

2022-500107-50-00 hilar cholangiocarcinoma 6 2022-10-12
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting

2023-503267-42-00 Patients with a histological diagnosis of mismatch- rep 5 2022-06-10
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
Reduced intensity radio-chemotherapy for stage IIA/B seminoma Ended

2023-509663-24-00 Stage IIA/B seminoma 4 2020-08-20
Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera… Ended

2022-501973-37-00 Endometrial cancer 5 2020-01-30
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed … Ended

2022-502658-15-00 Resectable Stage II-IIIB Non-small cell lung cancer 5 2019-09-22
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02